Rheumatology International

, Volume 30, Issue 7, pp 863–869 | Cite as

Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat

Review Article

Abstract

Postmenopausal osteoporosis is a chronic condition due to decreased bone mass, leading to reduced bone strength and increased fracture risk. Currently available pharmacological treatments include antiresorptive agents (bisphosphonates and raloxifene) and bone-forming agents (strontium ranelate and two different parathyroid peptides). Comparison via reduction in relative risk of fracture may produce artificially high reductions in fracture risk for some agents. Responder analysis based on absolute risk reduction (ARR, the arithmetic difference between events rates with and without treatment over a fixed time) and a related parameter, number needed to treat (NNT, the number of patients needed to treat over a fixed time to prevent one event) may provide more reliable parameters. We reviewed placebo-controlled, randomized, double-blind, pivotal phase 3 trials employed as part of the regulatory process, in order to calculate ARRs and NNTs for vertebral and hip fracture over 3 years for antiosteoporotic agents currently available in Europe. The NNT values to prevent one vertebral fracture over 3 years range from 9 for the strontium ranelate to 21 for ibandronate. NNT values for hip fracture over 3 years range from 48 for strontium ranelate to 91 for three of the bisphosphonates. Our analysis indicates that the bone-forming agent strontium ranelate may have the lowest NNT for the prevention of both vertebral and hip fracture. Responder analysis may enable translation of clinical trial results into guidance for routine clinical practice by indicating the amount of effort needed to prevent the same event in comparable populations with different treatment options.

Keywords

Osteoporosis Bisphosphonates Strontium ranelate Absolute risk reduction 

Notes

Acknowledgments

J. D. Ringe has received congress grants and honoraria from Sanofi Aventis; MSD, Novartis, P&G, Roche and Servier; J. G. Doherty has received educational, travel, and congress grants from MSD, Alliance for Better Bone Health, Lilly, and Servier.

References

  1. 1.
    US Department of Health and Human Services (DHHS) (2003) Report of the surgeon general’s workshop on osteoporosis and bone health, pp 1–100. Available at http://www.surgeongeneral.gov/library/bonehealth/index.html. Accessed 11 Dec 2009
  2. 2.
    Reginster J-Y, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4–S9CrossRefPubMedGoogle Scholar
  3. 3.
    Oden A, Dawson A, Dere W et al (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599–603CrossRefPubMedGoogle Scholar
  4. 4.
    van Schoor NM, Smit JM, Twisk JW et al (2003) Prevention of hip fractures by external hip protectors: a randomized controlled trial. JAMA 289:1957–1962CrossRefPubMedGoogle Scholar
  5. 5.
    Grant AM, Avenell A, Campbell MK et al (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomised evaluation of calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621–1628CrossRefPubMedGoogle Scholar
  6. 6.
    Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683CrossRefPubMedGoogle Scholar
  7. 7.
    Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMedGoogle Scholar
  8. 8.
    Alonso-Coello P, Garcia-Franco AL, Guyatt G et al (2008) Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 336:126–129CrossRefPubMedGoogle Scholar
  9. 9.
    Barratt A, Wyer PC, Hatala R et al (2004) Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 171:353–358PubMedGoogle Scholar
  10. 10.
    Replogle WH, Johnson WD (2007) Interpretation of absolute measures of disease risk in comparative research. Fam Med 39:432–435PubMedGoogle Scholar
  11. 11.
    Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293–300CrossRefPubMedGoogle Scholar
  12. 12.
    Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310:452–454PubMedGoogle Scholar
  13. 13.
    McQuay HJ, Moore RA (1997) Using numerical results from systematic reviews in clinical practice. Ann Intern Med 126:712–720PubMedGoogle Scholar
  14. 14.
    Seeman E, Eisman JA (2004) 7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual’s absolute risk of fracture. Med J Aust 180:298–303PubMedGoogle Scholar
  15. 15.
    Committee for Medicinal Products for Human Use (CHMP) (2007) Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorisation applications of medicinal products for human use. http://www.emea.europa.eu/pdfs/human/brmethods/1540407en.pdf. Accessed 9 Oct 2009
  16. 16.
    Sox HC (2007) Straight talk about disease prevention. Ann Intern Med 146:891–892PubMedGoogle Scholar
  17. 17.
    MacLaughlin EJ, Raehl CL (2008) ASHP therapeutic position statement on the prevention and treatment of osteoporosis in adults. Am J Health Syst Pharm 65:343–357CrossRefGoogle Scholar
  18. 18.
    Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMedGoogle Scholar
  19. 19.
    Chesnut CH, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  20. 20.
    Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMedGoogle Scholar
  21. 21.
    Cosman F, Borges JL, Curiel MD (2007) Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Clin Ther 29:1116–1127CrossRefPubMedGoogle Scholar
  22. 22.
    Adami S (2007) Bisphosphonate antifracture efficacy. Bone 41:S8–S15CrossRefGoogle Scholar
  23. 23.
    Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMedGoogle Scholar
  24. 24.
    Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637–645CrossRefPubMedGoogle Scholar
  25. 25.
    McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340CrossRefPubMedGoogle Scholar
  26. 26.
    Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468CrossRefPubMedGoogle Scholar
  27. 27.
    Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
  28. 28.
    Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822CrossRefPubMedGoogle Scholar
  29. 29.
    Agence Française de Sécurité Sanitaire des Produits (2006) Traitement de l’ostéoporose post-ménopausique. http://afssaps.sante.fr/pdf/5/rbp/ostemarg.pdf. Accessed 9 Oct 2009
  30. 30.
    Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687–1695CrossRefPubMedGoogle Scholar
  31. 31.
    Curtis JR, Westfall AO, Cheng H et al (2008) The benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23:1435–1441CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Med Klinik 4, Klinikum Leverkusen, AkademLehrkrankenhaus University of CologneCologneGermany
  2. 2.Department of Rheumatology and Osteology, West German Osteoporosis Center (WOC), Klinikum LeverkusenUniversity of CologneCologneGermany
  3. 3.Department of Medicine and OrthogeriatricsSligo General HospitalSligoIreland
  4. 4.National University of IrelandGalwayIreland

Personalised recommendations